Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178280 | 1.00 | LMNA (0.42) | LMNAKCNA5RAB9APDE4DSMN1; SMN2 | |
| SCHEMBL6954924 | 0.84 | KCNA5 (0.56) | LMNAKCNA5PDE4DSMN1; SMN2L3MBTL1 | |
| SCHEMBL2298713 | 0.84 | KCNA5 (0.56) | LMNAKCNA5PDE4DSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL15146071 | 0.83 | KCNA5 (0.55) | LMNAKCNA5PDE4DSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6954054 | 0.83 | KCNA5 (0.55) | LMNAKCNA5PDE4DSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6947507 | 0.83 | KCNA5 (0.55) | LMNAKCNA5PDE4DSMN1; SMN2L3MBTL1 | |
| SCHEMBL28275305 | 0.82 | LMNA (0.38) | LMNAKCNA5GRM8GRM4 | |
| SCHEMBL28274163 | 0.82 | LMNA (0.38) | LMNAKCNA5GRM8GRM4 | |
| SCHEMBL6985627 | 0.82 | CYP2D6 (0.34) | CYP3A4CYP3A5 | |
| SCHEMBL6243723 | 0.82 | KCNA5 (0.42) | LMNAKCNA5RAB9APDE4DSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744252-B2 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2017-08-29 | — | — | US | disclosed |
| EP-2744802-B1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| US-9345793-B2 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2016-05-19 | — | — | US | disclosed |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | F13B, FGB, SELPLG | LMNA 3622/4885KCNA5 2123/4885RAB9A 806/4885 |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | F13B, FGB, SELPLG | LMNA 3622/4885KCNA5 2123/4885RAB9A 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.